Dr. Lal PathLabs held its Q2 & H1 FY27 Earnings Conference Call on November 04, 2026. The call duration was 56 minutes 11 seconds and was moderated by Nishid Solanki from CDR India.

Management Participants:

  • (Hony) Brig. Dr. Arvind Lal - Executive Chairman
  • Mr. Shankha Banerjee - Chief Executive Officer
  • Mr. Ved Prakash Goel - Group CFO and CEO, International Business

Financial Highlights for Q2 FY27:

  • Revenue: Rs. 874 crore (19.6% YoY growth)
  • Patient Volume: 9 million (9% growth)
  • Sample Volume: 28.8 million (13.6% growth)
  • Revenue per Patient: Rs. 976 (9.7% growth)
  • EBITDA: Rs. 280 crore (25.1% growth) with margin of 32.1%
  • PBT: Rs. 261 crore (28.1% growth) with margin of 29.8%
  • PAT: Rs. 194 crore (27.5% growth) with margin of 22.2%
  • EPS: Rs. 11.5 compared to Rs. 9 in Q2 FY26

H1 FY27 Performance:

  • Revenue: Rs. 1,672 crore (19.4% growth)
  • EBITDA: Rs. 528 crore (26.7% growth) with margin of 31.6%
  • PAT: Rs. 364 crore (27.3% growth) with margin of 21.8%
  • EPS: Rs. 21.7 compared to Rs. 17 in H1 FY26

Strategic Updates:

  • Completed acquisition of S N GeneLab Private Limited to strengthen genomics expertise
  • Acquired remaining 30% stake in Centrapath Labs, making it a wholly owned subsidiary
  • Board declared second interim dividend of 50% (Rs. 5 per share)
  • Net cash position of Rs. 1,746 crore as of September 30, 2026
  • Net working capital remained negative at 16 days

Guidance:

  • Revenue guidance for FY27: high teens growth
  • EBITDA margin expected to be slightly better than last year's 27.2%
  • Long-term sustainable organic revenue growth in mid-teens

Business Developments:

  • Launched approximately 140 new tests during H1 FY27, including 2 first-in-India assays
  • Rolled out new physical patient report format with trend charts and anti-counterfeit features
  • Established enterprise-wide foundation for digital pathology with AI-ready platform
  • International expansion through acquisition in Ghana and JV in Uzbekistan
  • Rural outreach program gaining strength in seven states

Additional Notes Section

The document includes the complete transcript of the earnings conference call. No financial data beyond what was disclosed in the transcript was included in the announcement. The company included standard forward-looking statement disclaimers.